Login to Your Account

CuraGen, TopoTarget Form HDAC Inhibitor Deal Worth Up To $100M

By Karen Pihl-Carey

Monday, June 7, 2004
As it transforms itself from a genomics discovery company to a product development company, CuraGen Corp. in-licensed a promising cancer compound from the Danish firm TopoTarget A/S. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription